Increasing patient savings and reducing government spending are laudable goals. But neither the CBO nor Precision experts Jeremy Schafer, Jacki Chou, and Harry G. Schiavi believe the proposed HHS rule will work. In this Spotlight on Market Access article, they join other industry leaders in discussing the potential repercussions of the rule.
The Health Care Ecosystem and Social Determinants of Health: Surveys Suggest the State is Set for Novel Combinations
Precision for Value, Senior Vice President, Director of Value Transformation, Maureen Hennessey brings her personal experience to bear in this important Journal of Clinical Pathwaysˆ article on the social determinants of health—exploring where things stand now and opportunities for improvement.
Read the full article here.
HHS wants to eliminate drug rebates in Medicare Part D and Medicaid managed care. But the CBO projects the resulting higher premiums will cost the government dearly. In an AIS Health, Radar on Specialty Pharmacy article, Jeremy Schafer, Precision for Value Senior Vice President, Access Experience, weighs in on the potential impact of the rule, and what that means for its future. (more…)
When high out-of-pocket costs spur noncompliance that leads to increased hospitalization, payers take notice. Using therapies for COPD as a case in point, AIS Health, Radar on Drug Benefits interviews Precision for Value Vice President, Access Experience, Charline Shan about the strategies payers may take to lower costs for their beneficiaries—and themselves.
The launch of a new RA biosimilar is being held up in court—and the outcome of the lawsuit will have far-reaching impact on prices. Jeremy Schafer, Precision for Value Senior Vice President and director of the Access Experience Team, explains why in formularywatch.
The definition of personalized medicine has expanded beyond tailored medical treatment to encompass drug development, care delivery and consumer engagement—while precision medicine refers to the tailoring of medical treatment to the characteristics of a patient subpopulation. This PharmaVoice cover story explores the distinctions, the challenges and the implications, including insights from Precision for Medicine’s own Chad Clark.
The FDA approved it in 2016, but the question remains: Is real-world evidence a suitable substitute for randomized clinical trials? Knect365 interviews Dan Danielson, Senior Director of the Access Experience Team at Precision for Value, on the opportunities and challenges of real-world evidence.
Managed Healthcare Executive asked leaders to describe the most important factors in building a successful team. Dan Renick, President, Precision Value & Health, stresses the value of investing in the team. See why—and get other leadership insights in this engaging slideshow.
ADDITIONS OF KEY FORMER PAYER DECISION MAKERS COX, DANIELSON, AND LOPATA WILL PROVIDE CLIENTS WITH WINNING STRATEGIES TO ADDRESS LATEST TRENDS IN
RAPIDLY CHANGING HEALTHCARE MARKETPLACE
Precision Value & Health recently surveyed 25 key decision makers at leading health plans and delivery networks regarding gene therapy—including who should be treated and when. STAT shares the intriguing results in this article by Jeremy Shafer, Senior VP of Access Experience, Precision for Value. Hint: cost isn’t the only answer.